Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31339222 | 0.85 | KMT2A (0.64) | KMT2AHPGDRAB9AMEN1NPC1 | |
| SCHEMBL9314349 | 0.85 | KMT2A (0.64) | KMT2AHPGDRAB9AMEN1NPC1 | |
| SCHEMBL13485305 | 0.82 | HPGD (0.67) | KMT2AHPGDRAB9AMEN1NPC1 | |
| SCHEMBL8284968 | 0.80 | KMT2A (0.62) | KMT2AHPGDRAB9AMEN1NPC1 | |
| SCHEMBL355357 | 0.80 | ALDH1A1 (0.59) | KMT2ARAB9ANPC1TDP1GAA | |
| SCHEMBL3717527 | 0.79 | KMT2A (0.72) | KMT2ARAB9AMEN1NPC1LMNA | |
| Hydrochloric Acid SCHEMBL1375604 | 0.79 | ALDH1A1 (0.62) | KMT2ARAB9ANPC1TDP1GAA | |
| SCHEMBL3077349 | 0.79 | KMT2A (0.56) | KMT2AHPGDRAB9AMEN1NPC1 | |
| SCHEMBL1327237 | 0.79 | KMT2A (0.56) | KMT2AHPGDRAB9AMEN1NPC1 | |
| SCHEMBL934289 | 0.79 | KMT2A (0.56) | KMT2AHPGDRAB9AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5286721-A | Antimicrobial agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-02-15 | — | — | US | claimed |
| EP-0506982-A1 | 1-AZABICYCLO 3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | claimed |
| WO-1992006978-A1 | 1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-30 | — | — | WO | claimed |
| EP-3471729-B1 | ISOXAZOLMETHYLTHIO-, THIENYLMETHYLTHIO- AND THIAZOMETHYLTHIO-DERIVATIVES FOR USE IN THE TREATMENT OF CANCER; VIRAL INFECTIONS; THROMBOTIC EVENTS OR PLATELET AGGREGATION | UNIV RUTGERS (US) | 2023-02-22 | — | — | EP | disclosed |
| US-7666869-B2 | to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents | MITSUBISHI TANABE PHARMA CORP. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-5286721-A | Antimicrobial agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-02-15 | — | — | US | disclosed |
| EP-0506982-A1 | 1-AZABICYCLO 3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-07 | — | — | EP | disclosed |
| WO-1992006978-A1 | 1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | KMT2A 1395/4885HPGD 3702/4885RAB9A 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.